PhOx430
Advanced Solid Tumors
Phase 1/2Active
Key Facts
About Phost'in Therapeutics
Phost'in Therapeutics is a clinical-stage biotech developing first-in-class oral inhibitors of aberrant N-glycosylation, a novel immune checkpoint. Its lead asset, PhOx430, is in an adaptive Phase I/II trial (PhAST) for advanced solid tumors and has shown strong preclinical efficacy with a favorable safety profile. The company has secured significant non-dilutive funding from French government initiatives and a strategic option/license agreement with Taiho Pharmaceutical, validating its platform's potential in oncology and chronic fibrosis. Backed by strong academic IP and a lean management team, Phost'in is positioned at the intersection of glycoscience and immuno-oncology.
View full company profileOther Advanced Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| NT219 | Purple Biotech | Phase 1/2 |
| INDP-101 | Indaptus Therapeutics | Phase 1 |
| NST-101 (estimated) | Novastage Pharmaceuticals | Phase 1/2 |
| Meta10-TILs | Leman Biotech | Phase 1 |
| PM14 | PharmaMar | Phase 1/2 |
| Ecubectedin (PM54) | PharmaMar | Phase 1 |
| M8891 | Merck KGaA | Phase 1/2 |
| P-002 | Panacea Biotec | Phase 1/2 |
| Undisclosed kinase inhibitor | Tyligand Bioscience | Phase 1 |
| TYK-001 | TYK Medicines | Phase 1/2 |
| PT-112 | SciClone Pharmaceuticals | Phase 1 |
| AP-202 | Advance Pharmaceutical | Phase 1/2 |